research All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Are Relevant to Identify and Detect Changes in Skin Activity
The Phase 2 LILAC study (N=132) demonstrated the efficacy of litifilimab in reducing disease activity in patients with active cutaneous lupus erythematosus (CLE), as measured by the CLASI-A score, which evaluates five clinical subcomponents: Erythema, Scale/Hypertrophy, Mucous Membrane Lesions, Recent Hair Loss, and Non-scarring Alopecia. Significant improvements were observed at Week 16, particularly in sunlight-exposed areas, with up to 33.3% of participants showing a 1-point improvement in Erythema. The study confirmed that no single subcomponent solely drives the CLASI-A score, highlighting the importance of all subcomponents in assessing CLE disease activity.
